ROBO1, a tumor suppressor and critical molecular barrier for localized tumor cells to acquire invasive phenotype: Study in African‐American and Caucasian prostate cancer models

High‐risk populations exhibit early transformation of localized prostate cancer (CaP) disease to metastasis which results in the mortality of such patients. The paucity of knowledge about the molecular mechanism involved in acquiring of metastatic behavior by primary tumor cells and non‐availability of reliable phenotype‐discriminating biomarkers are stumbling blocks in the management of CaP disease. Here, we determine the role and translational relevance of ROBO1 (an organogenesis‐associated gene) in human CaP. Employing CaP‐progression models and prostatic tissues of Caucasian and African‐American patients, we show that ROBO1 expression is localized to cell‐membrane and significantly lost in primary and metastatic tumors. While Caucasians exhibited similar ROBO1 levels in primary and metastatic phenotype, a significant difference was observed between tumor phenotypes in African‐Americans. Epigenetic assays identified promoter methylation of ROBO1 specific to African‐American metastatic CaP cells. Using African‐American CaP models for further studies, we show that ROBO1 negatively regulates motility and invasiveness of primary CaP cells, and its loss causes these cells to acquire invasive trait. To understand the underlying mechanism, we employed ROBO1‐expressing/ROBO1‐C2C3‐mutant constructs, immunoprecipitation, confocal‐microscopy and luciferase‐reporter techniques. We show that ROBO1 through its interaction with DOCK1 (at SH3‐SH2‐domain) controls the Rac‐activation. However, loss of ROBO1 results in Rac1‐activation which in turn causes E‐Cadherin/β‐catenin cytoskeleton destabilization and induction of cell migration. We suggest that ROBO1 is a predictive biomarker that has potential to discriminate among CaP types, and could be exploited as a molecular target to inhibit the progression of disease as well as treat metastasis in high‐risk populations such as African‐Americans. What's new? While African‐American prostate‐cancer patients are known to have an increased risk of developing aggressive, metastatic disease, the molecular mechanisms are not well understood. In this study, the authors found that ROBO1 acts as a tumor‐suppressor gene, and is expressed differently in primary vs metastatic tumors in African‐American patients. ROBO1 may thus provide a valuable predictive biomarker for distinguishing between indolent and metastatic prostate cancer in high‐risk populations. It may also provide a useful therapeutic target for metastatic CaP in these pati